不怕开水烫 发表于 2024-1-17 20:36
能开展飞蚊症的数据收集 那就说明糖网的治疗进展顺利 可以猜测 治疗玻璃体浑浊的设备和糖网设备必然有大 ...
我担心的只有一点，飞秒激光目前还没有实际用于玻璃体混浊的治疗，这次临床实验仅限于成像，成像技术做好之后还要另外开展打激光的实验，这又要花费一段时间。而飞秒激光的安全性和有效性如何也只有在实际应用中才能知道。总之技术的进步一定是有的，就是不知道能否进步到我们期待的那样。但愿可以吧。
还有这次临床招募应该仅限于加拿大或者北美地区吧？希望外国网友们能在他们当地的论坛下多宣传这个消息，让公司早日招满志愿者，尤其是年轻患者一定不能少，毕竟在对飞蚊症的研究中最缺乏的就是年轻人的数据。
1234567 发表于 2024-1-17 20:44
我担心的只有一点，飞秒激光目前还没有实际用于玻璃体混浊的治疗，这次临床实验仅限于成像，成像技术做好 ...
我反而觉得 激光效用方面用不担心 从企业的研发方向来说 德国的Xfloater和比利时金纳米还有爱尔康的专利申请 都表明飞秒激光治疗飞蚊是有效果的 否则众多机构不会都朝这个方向使劲 另外就是从企业赚钱的角度讲 研发这个激光设备 肯定会在一开始就用简易设备测试过可行性 不然开发了半天成像设备 AI追踪成像 最后激光不能消融浑浊 那前期投资就浪费了 所以不用担心激光的效用性
1234567 发表于 2024-1-17 20:47
还有这次临床招募应该仅限于加拿大或者北美地区吧？希望外国网友们能在他们当地的论坛下多宣传这个消息，让 ...
不止北美 还有南美
图里第一个是糖网的临床计划 现在已经结束了
第二和第三个是这次飞蚊症拍照建模的招募 第二个的地点是加拿大的蒙大拿 第三个地点是巴拿马的巴拿马眼科中心 两个同时开始 每个招募125名患者
或许在reddit等国外论坛上宣传下更好
感觉各项研究和进展都市奔着3年后去的，包括药物
短期内没有什么能反复研究和讨论的新技术了
希望pulsemedica能顺利上市，哪怕十年也好。
SimRace 发表于 2024-1-18 10:35
感觉各项研究和进展都市奔着3年后去的，包括药物
短期内没有什么能反复研究和讨论的新技术了
希望pulsemedi ...
之后引进国内还要3年，如果顺利差不多2030年用上
本帖最后由 SimRace 于 2024-1-18 11:08 编辑
这是临床链接的官网，可以看到三次临床试验
https://classic.clinicaltrials.g ... &state=&city=&dist=
我会把它转到Reddit 和 Facebook
https://www.reddit.com/r/EyeFloaters/comments/199fm6u/the_latest_news_from_pulsemedica_they_started/
I saw this on a Chinese forum and am reposting it here. Pulsemedica is recruiting participants for a clinical trial, please actively participate:
"Friends on the forum know that I have been following the progress of the Pulsemedica company's project in Canada. This time, I got the latest updates from the official U.S. clinical recruitment website. It's a mix of good and bad news.
Let me first interpret the picture: Starting with the good news: there is indeed a plan to develop treatment for vitreous opacities. The screenshot shows clinical recruitment information published on January 12, 2024. The clinical trial begins in February 2024 and is expected to end in September 2024. As you can see, the clinical information clearly mentions floaters and VOs (vitreous opacities). So, at least it's clear that Pulsemedica's scope of business is not limited to just treating diabetic retinopathy, as previously rumored online.
Now the bad news: This clinical trial is only collecting photographic models and information about vitreous opacities to establish a database for future treatments. You can see that the model of this equipment is different from the one used in the previous diabetic retinopathy clinical trial. This means that the previous prediction of the device being marketed in 2024 is not going to happen.
This leads to many new questions: After completing the collection of models and database information for floaters, what comes next is how to treat them, whether they can be treated, and what the effects are. If treatment is possible, how long before the equipment is marketed? I optimistically estimate that if there is a treatment plan and effective results, it could be brought to market by the end of 2025. A pessimistic estimate would be that the treatment effects are limited, with a new clinical announcement in 2026.
Finally, I ask my fellow patients to please share this post and expand its impact. Thank you for your attention."
已发帖，希望reddit上有人响应
我关注到pulsemedic去年10月和今年1月的两次临床表述上的不同：
10月是：
Evaluation of a Non-Invasive Imaging Device for the Acquisition of Imaging Data of Vitreous Opacities in Human Eyes
1月是：
Acquisition of Imaging Data of Vitreous Opacities in Human Eyes Using a Non-Invasive Imaging Device
他们确实在缓慢推进，希望到了关键节点，能得到更多的钱和资源，加速他们的产品上市，无论是直接用于治疗还是卖给大厂。总之，期待吧。